A Multiplex Assay to Measure RNA Transcripts of Prostate Cancer in Urine

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Quek, Sue Ing ^a,b   Ho, Melissa E ^a,b   Loprieno, Michelle A ^a,b   Ellis, William J ^a   Elliott, Nathan ^c   Liu, Alvin Y ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NANOSTRING TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; TRANSCRIPTOME;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN CELL; HYBRIDIZATION; NANOSTRING NCOUNTER TECHNOLOGY; NANOTECHNOLOGY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RNA ANALYSIS; RNA DEGRADATION; RNA EXTRACTION; RNA PURIFICATION; RNA TRANSCRIPTION; URINALYSIS;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84866693498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045656     Document Type: Article

References (34)

1. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Eng J Med 350: 2239-2246.
2. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, et al. (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19: 1193-1200.
3. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26: 317-325.
4. Pascal LE, Vêncio RZN, Page LS, Liebeskind ES, Shadle CP, et al. (2009) Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 9: 452.
5. Pascal LE, Goo YA, Vêncio RZN, Page LS, Chambers AA, et al. (2009) Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer 9: 317.
6. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, et al. (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095.
7. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, et al. (2008) A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389: 1-6.
8. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, et al. (2010) Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 70: 10-16.
9. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, et al. (2012) The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int, Epub.
10. Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, et al. (2006) Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia 8: 153-162.
11. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, et al. (2005) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114: 950-956.
12. Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, et al. (2009) High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest 119: 1714-1726.
13. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
14. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY, (2005) AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 43: 249-259.
15. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, et al. (2000) Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60: 1677-1682.
16. Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G, (2002) Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res 62: 3308-3314.
17. Magee JA, Araki T, Patil S, Ehrig T, True L, et al. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696.
18. Bussemakers MJG, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HFM, et al. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979.
19. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
20. Liu AY, Roudier MP, True LD, (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165: 1543-1556.
21. True LD, Zhang H, Ye M, Huang C, Nelson PS, et al. (2010) CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol 23: 1346-1356.
22. Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, et al. (1999) Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol 6: 286-292.
23. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, et al. (2005) Application of Affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 5: 86.
24. Sobel RE, Sadar MD, (2005) Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol 173: 342-359.
25. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, et al. (1998) Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887-894.
26. Wayner EA, Quek SI, Ahmad R, Ho ME, Loprieno MA, et al. (2011) Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate 72: 1023-1034.
27. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, et al. (2003) Expression of alpha-methylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34: 792-796.
28. Udby L, Bjartell A, Malm J, Egesten A, Lundwall A, et al. (2005) Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. J Androl 26: 333-342.
29. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, et al. (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12: 590-598.
30. Liu AY, Vêncio RZN, Page LS, Ho ME, Loprieno MA, et al. (2012) Bladder expression of CD cell surface antigens and cell type-specific transcriptomes. Cell Tissue Res 348: 589-600.
31. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, et al. (2011) The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 109: 360-366.
32. Bu H, Bormann S, Schäfer G, Horninger W, Massoner P, et al. (2011) The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71: 575-587.
33. Gorin MA, Eldefrawy A, Ekwenna O, Soloway MS, (2011) Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer Prostate Dis 15: 177-181.
34. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, et al. (2010) Canary prostate active surveillance study: design of a multi-institutional active surveillance cohort and biorepository. Urology 75: 407-413.